Studie perorálního agonisty TLR8 selgantolimodu na HBsAg u účastníků s chronickou hepatitidou B a HIV
Bezpečnost, snášenlivost a dopad perorálního agonisty TLR8 Selgantolimodu na HBsAg u účastníků s chronickou hepatitidou B i HIV
The study aimed to assess safety and tolerability of oral toll-like receptor (TLR) 8 agonist Selgantolimod (SLGN) administered for 24 weeks in participants with both chronic hepatitis B (CHB) and HIV who had received suppressive antiviral therapy for both viruses for ≥5 years and have qHBsAg level >1000 (3 log10) IU/mL at screening. The study also evaluated if TLR8 stimulation with SLGN will reduce hepatitis B surface antigen (HBsAg) titers in the blood.
The primary hypotheses of this study were:
- Administration of the oral TLR8 agonist SLGN will be safe and well-tolerated in participants with both CHB and HIV on suppressive antiviral therapy for both viruses.
- TLR8 stimulation with SLGN will reduce HBsAg titers in the blood of participants with both CHB and HIV on suppressive antiviral therapy for both viruses.
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Detailní popis
A5394 was a phase II, randomized, double-blind, placebo-controlled clinical trial to assess the safety, tolerability, and efficacy of 24 weeks of treatment with SLGN. Participants were randomized in a 3:1 ratio to receive SLGN or its placebo, and randomization was stratified by HBeAg status. Participants were planned to be on study for up to 48 weeks (24-week treatment phase and 24-week post-treatment follow-up). All participants were required to remain on their non-study-provided antiviral therapy throughout the study.
The primary efficacy analysis was planned to be conducted as a single-arm study of the SLGN study arm.
Accrual was terminated early and did not reach the target sample size of 48 due to ACTG Network funding disruptions.
Typ studie
Typ studie
Zápis (Aktuální)
Zápis
Fáze
Fáze
- Fáze 2
Kontakty a umístění
Studijní místa
-
-
-
Rio de Janeiro, Brazílie, 21040-360
- Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS (Site ID: 12101)
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brazílie, 91350-180
- Instituto de Pesquisas em AIDS do Rio Grande do Sul - IPARGS CRS (Site ID: 12201)
-
-
-
-
-
Lima, Peru, 04
- Barranco CRS (Site ID: 11301)
-
-
-
-
California
-
San Diego, California, Spojené státy, 92103
- UCSD Antiviral Research Center CRS (Site ID: 701)
-
-
Georgia
-
Atlanta, Georgia, Spojené státy, 30308
- The Ponce de Leon Center CRS (Site ID: 5802)
-
-
New York
-
New York, New York, Spojené státy, 10011
- Weill Cornell Chelsea CRS (Site ID: 7804)
-
-
North Carolina
-
Greensboro, North Carolina, Spojené státy, 27401
- Greensboro CRS (Site ID: 3203)
-
-
Ohio
-
Cincinnati, Ohio, Spojené státy, 45267-0405
- Cincinnati Clinical Research Site (Site ID: 2401)
-
Cleveland, Ohio, Spojené státy, 44106
- Case CRS (Site ID: 2501)
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Spojené státy, 15213
- Univ of Pittsburgh (Site ID: 1001)
-
-
-
-
-
Chiang Mai, Thajsko, 50200
- Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS (Site ID: 31784)
-
-
Bangkok
-
Pathum Wan, Bangkok, Thajsko, 10330
- Thai Red Cross AIDS Research Centre (TRC-ARC) CRS (Site ID: 31802)
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- HIV-1 infection
- Effective antiviral therapy for HIV (ART) and HBV that includes TDF, TAF, TDF/FTC, TDF/3TC (tenofovir disoproxil fumarate plus lamivudine), TAF/FTC, or entecavir (ETV), for ≥5 years immediately prior to study entry. ART is defined as including a minimum of two anti-HIV antivirals.
- CD4+ cell count ≥350 cells/mm3
- HIV-1 RNA <50 copies/mL measured on at least two occasions at least 12 weeks apart, with no documented value >200 copies/mL, over the 12 months prior to study entry.
- Positive or negative HBeAg
- Negative anti-HDV
- Current CHB infection
- HBV DNA level <50 IU/mL measured on at least two occasions at least 12 weeks apart, with no documented value ≥50 IU/mL, over the 12 months prior to study entry.
- Quantitative HBsAg >1000 IU/mL
- Hepatitis C virus (HCV) antibody negative, or if the participant is HCV antibody positive, an undetectable HCV RNA.
- Participants must agree to stay on an effective antiviral therapy for HIV (ART) and HBV throughout the study.
Exclusion Criteria:
- Receipt of treatment for HCV within 24 weeks prior to study entry
- Evidence of advanced fibrosis or cirrhosis (Metavir ≥F3 or equivalent).
- Current or prior history of clinical hepatic decompensation (e.g., ascites, encephalopathy, or variceal hemorrhage)
- History of HCC or cholangiocarcinoma
- Malignancy within 5 years prior to study entry. NOTE: A history of non-melanoma skin cancer (e.g., basal cell carcinoma or squamous cell skin cancer) is not exclusionary.
- History of solid organ transplantation
- Presence of any active or acute AIDS-defining opportunistic infections within 60 days prior to study entry
- History of uveitis or posterior synechiae
- Breastfeeding
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Trojnásobný
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Experimentální: Arm A
Participants received Selgantolimod 3 mg (two 1.5 mg tablets) once weekly for 24 weeks. |
Two 1.5 mg tablets taken orally once a week
Ostatní jména:
|
|
Komparátor placeba: Arm B
Participants received matching Placebo for Selgantolimod once weekly for 24 weeks. |
Two matching placebo tablets taken orally once a week |
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Proportion of Participants Who Experienced Grade ≥2 Adverse Events (AEs) in Arm A
Časové okno: From study treatment initiation through Week 24
|
An adverse event (AE) is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or diagnosis that occurs in a study participant during the conduct of the study REGARDLESS of the attribution. This includes any occurrence that is new in onset or aggravated in severity or frequency from the baseline condition. All AEs that are reported must have their severity graded. Adverse events were graded according to the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), corrected Version 2.1, July 2017. Adverse events were graded on a scale from 1-5: 1=mild, 2=moderate, 3=severe, 4=life-threatening, 5=death. Higher scores/grades mean a worse outcome. The proportion of participants with Grade 2 or higher adverse events was calculated, along with a two-sided 95% confidence interval constructed using the Clopper-Pearson exact method for binomial data. |
From study treatment initiation through Week 24
|
|
Proportion of Participants Who Prematurely Discontinued Treatment Due to Adverse Events (AEs) in Arm A
Časové okno: From study treatment initiation through Week 24
|
The proportion of participants who had premature discontinuation of Selgantolimod due to adverse event(s) was calculated, along with a two-sided 95% confidence interval constructed using the Clopper-Pearson exact method for binomial data. |
From study treatment initiation through Week 24
|
|
Proportion of Participants With ≥1 log10 IU/mL Decline From Baseline in Quantitative HBsAg (qHBsAg) After SLGN Treatment at Week 24
Časové okno: Week 24
|
The proportion of participants who experienced ≥1 log10 IU/mL decline in quantitative HBsAg at Week 24 was calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data. |
Week 24
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Proportion of Participants With ≥1 log10 IU/mL Decline From Baseline in qHBsAg at Any Time During the Study After SLGN Treatment Initiation
Časové okno: From Baseline (Entry) through Week 48
|
The proportion of participants who experienced ≥1 log10 IU/mL decline in quantitative HBsAg at any time during the study after SLGN treatment initiation will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data. |
From Baseline (Entry) through Week 48
|
|
Proportion of Participants With ≥0.5 log10 IU/mL Decline From Baseline in qHBsAg After SLGN Treatment at Week 24
Časové okno: Week 24
|
The proportion of participants who experienced ≥0.5 log10 IU/mL decline in quantitative HBsAg at Week 24 was calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data. |
Week 24
|
|
Proportion of Participants With ≥0.5 log10 IU/mL Decline in qHBsAg From Baseline at Any Time During the Study After SLGN Treatment Initiation
Časové okno: From Baseline (Entry) through Week 48
|
The proportion of participants who experienced ≥0.5 log10 IU/mL decline in quantitative HBsAg at any time during the study after SLGN treatment initiation will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data. |
From Baseline (Entry) through Week 48
|
|
Proportion of Participants Who Achieve HBsAg Loss After SLGN Initiation and Who Sustain HBsAg Loss During Follow-up
Časové okno: From Baseline (Entry) through Week 48
|
Sustained HBsAg loss is defined as HBsAg converting from positive to negative after initiation of SLGN, without any subsequent positive HBsAg result. The proportion of participants who achieved HBsAg loss after SLGN initiation and who sustained HBsAg loss during follow-up will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data. |
From Baseline (Entry) through Week 48
|
|
Changes From Baseline in qHBsAg Levels
Časové okno: Baseline (Entry) and Weeks 4, 12, 24, 36 and 48
|
The absolute change in qHBsAg level refers to the value at the follow-up time point minus the value at Baseline (Entry). |
Baseline (Entry) and Weeks 4, 12, 24, 36 and 48
|
|
Proportion of Hepatitis B E-antigen (HBeAg) Positive Participants at Baseline Who Lose HBeAg at Any Time During the Study
Časové okno: From Baseline (Entry) through Week 48
|
HBeAg loss is defined as HBeAg changing from positive to negative. The proportion of participants who lose HBeAg at any time during the study will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data. |
From Baseline (Entry) through Week 48
|
|
Proportion of Hepatitis B E-antibody (Anti-HBe) Negative Participants at Baseline Who Develop Anti-HBe at Any Time During the Study
Časové okno: From Baseline (Entry) through Week 48
|
Developing anti-HBe, or anti-HBe gain, is defined as HBeAb changing from negative to positive. The proportion of participants who develop HBeAb at any time during the study will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data. |
From Baseline (Entry) through Week 48
|
|
Proportion of Hepatitis B Surface Antibody (Anti-HBs) Negative Participants at Baseline Who Develop Anti-HBs at Any Time During the Study
Časové okno: From Baseline (Entry) through Week 48
|
Developing anti-HBs, or anti-HBs gain, is defined as HBsAb changing from negative to positive. The proportion of participants who develop HBsAb at any time during the study will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data. |
From Baseline (Entry) through Week 48
|
|
Number of Participants With Plasma HIV RNA >50 Copies/mL
Časové okno: Weeks 2, 4, 24 and 48
|
The number of participants with detectable plasma HIV RNA >50 copies/mL will be reported. |
Weeks 2, 4, 24 and 48
|
|
Number of Participants With Serum HBV DNA >50 IU/mL
Časové okno: Weeks 2, 4, 24 and 48
|
The number of participants with detectable serum HBV DNA >50 copies/mL will be reported. |
Weeks 2, 4, 24 and 48
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Spolupracovníci
Spolupracovníci
Publikace a užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Začátek studia
Primární dokončení (Aktuální)
Primární dokončení
Dokončení studie (Aktuální)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
- Infekce přenášené krví
- Urogenitální onemocnění
- Onemocnění genitálií
- Onemocnění imunitního systému
- Infekce
- RNA virové infekce
- Virová onemocnění
- Nemoci trávicího systému
- Onemocnění jater
- Hepatitida, virová, lidská
- Přenosné nemoci
- Pohlavně přenosné choroby, virové
- Pohlavně přenosné nemoci
- Lentivirové infekce
- Retroviridae infekce
- Syndromy imunologické nedostatečnosti
- DNA virové infekce
- Infekce Hepadnaviridae
- Hepatitida
- HIV infekce
- Žloutenka typu B
- Selgantolimod
Další identifikační čísla studie
Další identifikační čísla studie
- A5394
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Individual participant data that underlie results in the publication, after deidentification
Časový rámec sdílení IPD
Beginning 3 months following publication and available throughout period of funding of the Advancing Clinical Therapeutics Globally (ACTG) by NIH
Kritéria přístupu pro sdílení IPD
With whom? Researchers who provide a methodologically sound proposal for use of the data that is approved by the ACTG.
For what types of analyses? To achieve aims in the proposal approved by the ACTG.
By what mechanism will data be made available? Researchers may submit a request for access to data using the ACTG "Data Request" form at: https://actgnetwork.org/submit-a-proposal/. Researchers of approved proposals will need to sign an ACTG Data Use Agreement before receiving the data.
Typ podpůrných informací pro sdílení IPD
- PROTOKOL STUDY
- MÍZA
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .